184 related articles for article (PubMed ID: 6866310)
1. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
Scolozzi R; Boccafogli A
Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
[TBL] [Abstract][Full Text] [Related]
2. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293
[No Abstract] [Full Text] [Related]
3. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
4. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
5. [Multiple myeloma transforming into acute leukaemia (author's transl)].
Mayans J; Redon J; Badia L; Herranz C; Calabuig JR; Sanz MA; Soler A; Caballero M; Marty ML
Sangre (Barc); 1977; 22(6):1026-9. PubMed ID: 601670
[No Abstract] [Full Text] [Related]
6. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
[No Abstract] [Full Text] [Related]
7. [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan].
Morlock G; Bataille R; Sany J; Serre H
Sem Hop; 1977 Apr 9-16; 53(14-15):853-6. PubMed ID: 194338
[No Abstract] [Full Text] [Related]
8. [Intermittent low dose melphalan and prednisone in multiple myeloma].
Yalon M; Levo Y; Many A; Ramot B
Harefuah; 1977 Apr; 92(7):296-8. PubMed ID: 863310
[No Abstract] [Full Text] [Related]
9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
10. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
11. Alkeran and multiple myeloma.
Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
[No Abstract] [Full Text] [Related]
12. [Case of IgG-K myeloma successfully treated with melphalan but terminating in acute myelogenous leukemia 2 years and 8 months later].
Saitoh A; Tsushima T; Narita K; Fujiwara S; Kawamura S; Chiba Y; Yoshida Y
Rinsho Ketsueki; 1982 Jun; 23(6):862-9. PubMed ID: 6960198
[No Abstract] [Full Text] [Related]
13. Secondary myelodysplastic syndrome in multiple myeloma--a study of nine patients with an attempt to detect myeloma patients at risk.
Mittelman M; Lewinski UH; Weiss H; Cohen AM; Djaldetti M; Pick AI
Haematologia (Budap); 1994; 26(2):67-74. PubMed ID: 7890264
[TBL] [Abstract][Full Text] [Related]
14. [Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
Rubio Felix D; Giraldo MP; Raichs A; García Zueco JC; Mur P; Faura MV; Ruíz-Marcuello E; Piñan MA
Sangre (Barc); 1980; 25(1):25-34. PubMed ID: 7384962
[No Abstract] [Full Text] [Related]
15. [Cytomorphological, immunochemical and therapeutic aspects of multiple myeloma].
Maroncelli P; Casalino C
Minerva Med; 1973 Feb; 64(8):337-57. PubMed ID: 4120544
[No Abstract] [Full Text] [Related]
16. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
17. Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy.
Donofrio PD; Albers JW; Greenberg HS; Mitchell BS
Muscle Nerve; 1984 Feb; 7(2):137-41. PubMed ID: 6325905
[TBL] [Abstract][Full Text] [Related]
18. [Multiple myeloma in stage I. Evaluation of the initial therapy].
Zapatero A; Blanco L; Sevilla F; Escribano L; Odriozola J; Montalbán C
Rev Clin Esp; 1985 May; 176(8):388-91. PubMed ID: 4023320
[No Abstract] [Full Text] [Related]
19. [Erythroleukemia in multiple myeloma. A case report].
Streuli R; Voellmy W
Schweiz Med Wochenschr; 1987 Feb; 117(8):286-91. PubMed ID: 3470922
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
Prescrire Int; 2009 Apr; 18(100):49-52. PubMed ID: 19585712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
